Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Delta(DAL) Seeking Alpha·2024-02-28 04:56peakSTOCK/iStock via Getty ImagesVir Biotechnology (NASDAQ:VIR) is developing treatments for patients with Hepatitis B (HB), Hepatitis delta (HD), Human Immunodeficiency Virus (HIV), Influenza and COVID. I wrote about the name in November 2023, rating it a buy based on an expectation of positive results from the company's ongoing work in HB and HD patients. The company also looked very cheap, with an enterprise value of over -$400M. Initial SOLSTICE data In November 2023, VIR reported the first data fro ...